<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="54">
  <stage>Registered</stage>
  <submitdate>22/07/2005</submitdate>
  <approvaldate>22/07/2005</approvaldate>
  <actrnumber>ACTRN12605000029695</actrnumber>
  <trial_identification>
    <studytitle>Tenofovir versus Adefovir for the treatment of HBeAg negative chronic hepatitis B</studytitle>
    <scientifictitle>A randomised, phase III, double blind study to evaluate the efficacy and safety of tenofovir DF versus adefovir dipivoxil in the treatment of presumed pre-core mutant chronic hepatitis B to suppress viral replication, amend the course of the disease and decrease morbidity.</scientifictitle>
    <utrn />
    <trialacronym>GS-US-174-0102</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>HBeAg negative Chronic Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To compare the efficacy of tenofovir DF 300 mg versus adefovir dipivoxil 10mg for the treatment of presumed pre-core mutany chronic hepatitis B over 48 weeks of treatment</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary efficacy parameter is the proportion of patients treated with tenofovir DF 300mg QD versus adefovir dipivoxil 10 mg QD with a complete response.   A complete response is defined as serum HBV DNA levels below 400 copies/mL and histologic improvement defined as at least a 2 point reduction in the Knodell necroinflammatory score without worsening in the Knodell fibrosis score.</outcome>
      <timepoint>At the end of the 48 week treatment period</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To compare the safety and tolerability of tenofovir DF 300 mg QD versus adefovir dipivoxil 10mg QD</outcome>
      <timepoint>Over the 48 week treatment period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the incidence of drug-resistant mutations between treatment arms and to compare the virological, serological, biochemical and histologic response of tenofovir DF 300mg QD versus adefovir dipivoxil 10mg QD for the treatment of presumed pre-core mutant chronic hepatitis B.</outcome>
      <timepoint>Over 48 weeks of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult patients (18-69 years of age) with presumed pre-core mutant chronic hepatitis B (HBsAg negative and HBsAg positive), HBsAg positive for more than 6 months with serum HBV DNA &gt;10 to the 5 copies /mL, ALT levels &gt;1.5 and less than or equal to 10x ULN and a Knodell necroinflammatory score of greater than or equal to 3 and a Knodell fibrosis score equal to 4 will be eligible for enrollment. However, up to 120 patients with cirrhosis, i.e. knodell fibrosis score equal to 4, will be eligible for enrollment. Patients who have not had a bopisy within 6 months at baseline must agree to undergo a liver biopsy prior to randomisation. No evidence of hepatocellular carcinoma (HCC) ie. fetoptotein &lt; 50 ng/mL at screening. Patients are eligible if they are treatment naive, ie less than 12 weeks of prior nucleoside or nucleotide (adefovir, dipivoxil or tenofovir DF) treatment, or with prior lamivudine experience of any duration. Enrollment of lamivudine experienced patients will be capped at up to 40% of the patient population (ie120 patients). Any previous treatment with nucleosides and nucleotides (eg up to 12 weeks) and interferon (pegylated or not) must have ended at least 6 months prior to the pre-treatment biopsy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>69</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients must be without HIV, HCV and HDV infection. Pregnant and breast feeding women will be excluded from the study and patients with decompensated liver disease or a history of decompensated liver disease (ascites, jaundice, encephalopathy or variceal haemorrhage) will be excluded from the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A centralised randomisation procedure will be used whereby numbered bottles will be assigned to patients via an interactive voice response system (IVRS) according to the randomisation code</concealment>
    <sequence>Randomly allocated by IVRS; stratified by prior nucleoside exposure and geographic region</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/08/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Gilead Sciences Inc</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Paul Desmond</name>
      <address>Department of Gastroenterolgy
St Vincent's Hospital Melbourne
41 Victoria Parade 
Fitzroy VIC 3065</address>
      <phone>+61 3 92883580</phone>
      <fax>+61 3 92883590</fax>
      <email>desmondpv@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Paul Desmond</name>
      <address>Department of Gastroenterolgy
St Vincent's Hospital Melbourne
41 Victoria Parade 
Fitzroy VIC 3065 </address>
      <phone>+61 3 92883580</phone>
      <fax>+61 3 92883590</fax>
      <email>desmondpv@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>